2016-09-02 18:14:30 UTC

Janssen to Provide Free Therapeutic Drug Monitoring for IBD Patients on Remicade

Sept. 2, 2016

You can leverage this program to evaluate how a patient is responding to Remicade and identify steps to optimize the patient’s response.

Janssen Biotech, Inc., has partnered with Miraca Life Sciences and its InformTx therapeutic drug monitoring service to develop the Janssen 2Inform program, which will provide two free therapeutic drug monitoring tests per year for patients with inflammatory bowel disease being treated with Remicade.

Through the program, therapeutic drug monitoring blood tests will be drawn from a patient and sent overnight to be analyzed by Miraca Life Sciences, which will then report results electronically to the physician within three-to-five business days. You can use these results to evaluate how a patient is responding to Remicade and, in turn, identify steps to optimize the patient’s response.

More information is available in this Healio Gastroenterology article.

More on IBD

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.